Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.
Hum Vaccin Immunother. 2012 Oct;8(10):1534-43. doi: 10.4161/hv.22064. Epub 2012 Oct 1.
Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.
变应原特异性免疫治疗(SIT)是唯一已知的治疗过敏性疾病的病因。基于重组变应原的疫苗接种策略的出现,既是为了提高安全性,也是为了增强 SIT 的疗效。此外,新型疫苗可有效治疗过敏症,包括食物过敏或特应性皮炎,这些过敏症对目前使用变应原提取物的治疗反应不佳。在过去十年中,已经有许多使用重组变应原疫苗的野生型和低变应原性衍生物的成功临床研究报告。它们显示出高效性和安全性,以及对特定变应原的 T 和 B 细胞反应的强烈调节作用。